Atlas FDA

TRIFORMIS RESILIA Tricuspid Valve

FDA premarket approval P150048/S092 · decided 2025-10-27

Approval details

PMA number
P150048
Supplement
S092
Supplement type
Panel Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
TRIFORMIS RESILIA Tricuspid Valve
Generic name
heart-valve, non-allograft tissue
Applicant
Edwards Lifesciences, LLC
Date received
2025-04-30
Decision date
2025-10-27
Days to decision
180 days
Decision code
APPR
Product code
LWR
Advisory committee
Cardiovascular
Expedited review
No
Location
Irvine, CA
Statement
Approval for the MITRIS RESILIA Mitral Valve for expanding the indications to include the tricuspid position. The device, as modified, will be marketed under the trade name “TRIFORMIS RESILIA Tricuspid Valve” and is indicated for the replacement of native or prosthetic tricuspid heart valves.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Respiration Rate algorithm (K251326)Edwards Lifesciences, LLC2026-06-11
HemoSphere Nano Monitor (HSNANO1) (K253186)Edwards Lifesciences, LLC2026-02-24
Edwards MC3 Tricuspid annuloplasty ring (4900) (K251982)Edwards Lifesciences, LLC2025-09-23
Carpentier-Edwards Physio Annuloplasty Ring (4450) (K251688)Edwards Lifesciences, LLC2025-09-17
Hypertension Prediction Index (HePI) Algorithm (K242518)Edwards Lifesciences, LLC2025-05-15
FloTrac sensors; FloTrac Jr sensors; Acumen IQ sensors; VolumeView sensors (K242909)Edwards Lifesciences, LLC2025-03-21
Fogarty Thru-Lumen Embolectomy Catheter (K240078)Edwards Lifesciences, LLC2024-08-28
Acumen Assisted Fluid Management (AFM) Software Feature (K233984)Edwards Lifesciences, LLC2024-08-02